T. Rowe Price Group

Nuro, Inc. is a technology company based in Mountain View, California, that specializes in the development of self-driving vehicles specifically designed for local goods transportation. Incorporated in 2016, Nuro aims to transform local commerce through its fleet of fully autonomous, electric vehicles that facilitate the delivery of a wide range of products, including food and pharmaceuticals. By enabling retailers to efficiently and safely deliver goods to customers, Nuro enhances the convenience of local commerce and meets the growing demand for autonomous delivery solutions.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Epirus, Inc. is a technology company based in Hawthorne, California, specializing in the design and development of advanced defense systems that utilize artificial intelligence and directed energy. Founded in 2018, the company focuses on creating solid-state, software-defined high-power microwave solutions aimed at countering unmanned aircraft systems and other asymmetric threats. Its flagship product, ELECTROMAGNETIC PULSE, serves as a counter-infrastructure solution that can simultaneously target multiple threats, effectively neutralizing drones and swarms. By integrating AI and machine learning with advanced electronics, Epirus enhances the detection and tracking of objects of interest, offering innovative capabilities in electronic warfare and power management for both defense and commercial sectors.

Eikon Therapeutics, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative treatments for chronic and life-threatening diseases. Established in 2019, the company employs advanced super-resolution microscopy and live-cell imaging techniques to discover drugs targeting previously intractable proteins. By directly measuring the interactions of chemical compounds with individual proteins within a live cellular environment, Eikon Therapeutics enhances the understanding of biological processes and supports the development of targeted therapies. The integration of biology, engineering, and chemistry in its proprietary platforms allows Eikon Therapeutics to streamline the drug discovery process, advance clinical programs, and expand its pipeline of potential medications.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive food analytics platform that utilizes next-generation sequencing and data analytics to enhance food safety and quality control. Its offerings include Clear Dx™ and Clear Safety™, which facilitate the rapid identification of pathogens and support public health initiatives. Clear Labs' platform delivers critical insights into the molecular composition of foods and ingredients, testing for authenticity, contaminants, allergens, and other safety parameters. By offering transparency across supply chains, the company serves food manufacturers, suppliers, and retailers, enabling them to improve operational efficiency and safety through detailed analytics and reporting.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating dialysis solutions for patients and healthcare providers. The company has developed the Tablo system, a hemodialysis machine designed for both acute and chronic care settings. Tablo features a compact console with integrated water purification, on-demand dialysate production, and advanced connectivity capabilities, including wireless data and sensor-based automation. This design aims to simplify the complexities and costs associated with dialysis, making it suitable for use in hospitals, dialysis clinics, and home settings. Originally founded as Home Dialysis Plus, Ltd. in 2003, the company rebranded to Outset Medical, Inc. in January 2015.

SandboxAQ is a company that develops artificial intelligence and quantum technology solutions aimed at addressing complex business and scientific challenges. By integrating expertise from multiple disciplines, including physics, computer science, and mathematics, the company creates Large Quantitative Models and AI sensing applications tailored for various industries. Its offerings are designed to provide practical solutions in sectors such as financial services, healthcare, telecommunications, and cybersecurity. Through its innovative software, SandboxAQ enables clients to tackle significant computational challenges and advance their technological capabilities.

nChroma Bio is a biotechnology company specializing in targeted genetic medicine. It operates an integrated product engine for safe, accurate, and targeted in vivo administration, aiming to overcome limitations of current genetic medicine techniques. The company focuses on liver-targeted therapies, initially for chronic hepatitis B and D, leveraging epigenetics to enable precise and specific gene regulation. This approach allows for therapies with programmable tissue specificity, potentially offering durable and targeted cures for the liver and other organs.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of treatment options, including both oral and injectable therapies, specifically targeting incretin, non-incretin, and combination approaches. By integrating proprietary health technology tools, Metsera aims to provide personalized care that meets the evolving demands of weight loss treatment. Its commitment to addressing multiple therapeutic targets positions the company to significantly impact the future of obesity management and related metabolic diseases.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for conditions with significant unmet needs. The company's approach emphasizes the creation of therapies that offer oral bioavailability, which allows for effective drug delivery while minimizing first-pass metabolism and reducing the risk of hepatotoxicity and other side effects. By addressing these critical challenges, Seaport Therapeutics aims to improve the quality of life for patients living with neuropsychiatric disorders.

Lightmatter, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in AI hardware development. The company pioneers integrated optical technology to create silicon chips that process data using light signals instead of electrical ones. This innovation aims to significantly accelerate AI computations, particularly in neural networks, while reducing power consumption. Lightmatter targets sectors such as artificial intelligence, cloud computing, and telecommunications.

Form Energy, Inc. is a company focused on developing long-duration energy storage systems aimed at transforming the electric grid by enabling the reliable use of renewable energy sources such as wind and solar. Established in 2017 and based in Somerville, Massachusetts, Form Energy is known for its innovative iron-air battery technology, which allows for the storage of electricity over extended periods, making renewable energy more dispatchable throughout the year. This technology not only helps to replace conventional fossil fuel-based generation but also enhances transmission capacity without the need for new infrastructure. By facilitating deep decarbonization of the electric system, Form Energy plays a significant role in reducing carbon emissions and promoting a sustainable energy future.

KoBold Metals is an AI-powered mineral exploration company focused on discovering essential materials for the electric vehicle and renewable energy sectors. The company combines advanced ore-deposit science with big data and scientific computing to enhance mineral exploration efforts. Its data platform aggregates and structures extensive scientific datasets, utilizing machine learning and other sophisticated analytical techniques to predict the composition of subsurface resources. By employing statistical association models and various analytical methods, KoBold Metals helps mineral exploration companies identify new sources of cobalt and other critical materials, thereby contributing to sustainable supply chains for the rapidly growing demand in electric vehicle production.

Aktis Oncology is a biotechnology company focused on the discovery and development of a new class of targeted radiopharmaceuticals aimed at treating various solid tumor cancers. The company has developed proprietary platforms to create tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered for high tumor penetration and prolonged residence time, allowing for effective tumor elimination while reducing the side effects typically associated with cancer treatments. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing treatment precision and efficacy.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.

MBX Biosciences, Inc. is a biotechnology company founded in 2018 and based in Carmel, Indiana. The company specializes in developing therapeutics for rare endocrine disorders, focusing on conditions that currently lack effective treatments. MBX Biosciences aims to discover, develop, and commercialize first-in-class therapies, particularly peptides designed to address endocrine genetic diseases that affect glandular hormone production and the body’s chemical messaging systems.

Kestra Medical Technologies, Inc. is a company that specializes in developing and manufacturing wearable medical devices aimed at monitoring and managing acute medical conditions. Founded in 2014 and headquartered in Kirkland, Washington, the company offers solutions that enable the collection, communication, and storage of patient performance data, facilitating both real-time and retrospective analysis. Among its key products are wearable cardioverter defibrillators designed to prevent sudden cardiac death and aid in the recovery of at-risk cardiac patients. By focusing on intuitive and mobile diagnostic and therapeutic technologies, Kestra Medical Technologies strives to enhance patient care and support healthcare teams in effectively managing patient health.

Waymo is a self-driving technology company focused on enhancing mobility by creating safe and efficient transportation solutions. Established from advancements in Google's research since 2009, Waymo aims to improve the movement of people and goods through its innovative software and sensor technology. In 2015, the company marked a significant milestone by conducting the world's first fully autonomous trip on public roads in a vehicle devoid of traditional driving controls. Waymo continually refines its technology through extensive simulation testing, accumulating over one billion miles of virtual testing annually, while its autonomous vehicles have logged more than two million miles on public roads in four U.S. cities. By employing integrated sensors and artificial intelligence, Waymo's technology is designed to detect various obstacles such as pedestrians, cyclists, and road conditions, ensuring a safe and convenient on-demand travel experience for users.

Clio is a Canadian company specializing in cloud-based practice management software for law firms. Its platform streamlines client management, billing, and communication, enabling lawyers to efficiently handle day-to-day tasks. Clio Ventures, an early-stage venture capital fund managed by Clio, invests in promising legal tech and SaaS startups, fostering innovation in the legal industry.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

PolicyBazaar Insurance Brokers Private Limited is an online platform based in Gurugram, India, that offers a range of insurance services, including life, health, car, two-wheeler, travel, and home insurance. Founded in 2014, the company provides a comparison portal and mobile application that enable users to analyze and compare various insurance products based on coverage, premiums, benefits, and exclusions. By doing so, PolicyBazaar helps consumers make informed decisions regarding their insurance needs. The platform also includes tools and calculators to assist users in estimating their insurance requirements. With a focus on creating awareness about financial impacts related to death, disease, and damage, PolicyBazaar generates the majority of its revenue from its insurance services segment, which includes insurance broker services.

Sila is a battery materials company founded in 2011 and headquartered in California, United States. It specializes in the production of energy-density lithium-ion batteries designed for electric vehicles, consumer electronics, and automotive original equipment manufacturers (OEMs). Sila focuses on enhancing energy storage solutions by developing supercharged battery materials that improve performance and longevity. Its products aim to facilitate the mass adoption of affordable, long-range electric vehicles while maintaining high standards of quality control, safety, and cycle life. By collaborating with battery manufacturers, Sila supports commercial cell production, driving innovation and efficiency in the battery technology sector.

Kardium Inc. is a medical solutions company based in Burnaby, Canada, specializing in advanced technologies for the diagnosis and treatment of atrial fibrillation (AF). Founded in 2007, Kardium has developed the Globe Mapping and Ablation System, which offers a comprehensive solution that includes single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation, all within a single catheter. This innovative system enhances the ability of medical practitioners to diagnose and treat cardiovascular diseases by providing detailed electrophysiological mapping and the application of radio-frequency energy to ablate cardiac tissue effectively. Kardium's team comprises experts in medicine, engineering, and business, all dedicated to advancing medical device technology in the field of electrophysiology.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing innovative CAR T-cell therapies to improve outcomes for cancer patients. The company aims to address the challenges faced by existing autologous CAR therapies, which are only curative for less than half of cancer patients and hindered by issues such as manufacturing limitations, supply challenges, and reimbursement barriers. Cargo Therapeutics is advancing next-generation cell therapies designed to enhance effectiveness, safety, and supply reliability. One of its key products, CRG-022, is a novel CAR T-cell candidate targeting CD22, an antigen present in a majority of B-cell malignancies, specifically designed to overcome treatment resistance. By pursuing these novel solutions, Cargo Therapeutics seeks to facilitate broader access to curative therapies and significantly improve the treatment experience for cancer patients.

BrightView Holdings Inc is a prominent provider of commercial landscaping services in the United States, employing over 18,000 individuals. The company specializes in a wide range of services, including landscape maintenance, enhancements, tree care, and landscape development. BrightView operates through two main segments: Maintenance Services and Development Services. Maintenance Services are primarily self-performed via a national branch network, focusing on route-based operations, while Development Services involve the design, coordination, and installation of landscapes for notable corporate, athletic, and university complexes. Serving a diverse clientele that includes corporate properties, public parks, healthcare facilities, educational institutions, and golf courses, BrightView is committed to creating exceptional landscapes that enhance the quality of life in the communities it serves.

Bluejay Therapeutics is a private biopharmaceutical company dedicated to developing curative treatments for infectious diseases, with an initial focus on chronic Hepatitis B. This disease remains prevalent worldwide and has significant unmet medical needs. The company is pursuing two innovative approaches: fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. These therapies aim to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially achieving a functional cure for patients.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Obsidian Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing next-generation cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Its innovative approach utilizes pharmacologic operating systems that enable precise control over protein activity within cells. This technology allows for the creation of adoptive cell therapies with novel functionalities, which can be regulated by treating physicians using simple and safe orally active medications. Through these advancements, Obsidian Therapeutics seeks to improve upon existing cell therapies and expand treatment options for a broader patient demographic.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Lambda is a technology company specializing in deep-learning infrastructure. It provides cloud computing services tailored for large-scale artificial intelligence training and inference. The company offers servers and workstations pre-configured with popular machine learning frameworks, allowing clients to simplify and accelerate the development of complex AI models for tasks such as natural language processing and drug discovery. Lambda's product range includes on-premises GPU hardware and cloud-hosted GPUs, empowering AI engineers to construct, test, and deploy AI products efficiently and securely at scale.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating novel antibody-based therapeutics aimed at treating cancer. The company utilizes innovative proprietary technology platforms to develop a diverse pipeline of antibody-drug conjugate (ADC) candidates that target both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus on advancing targeted therapeutics leverages the immune system's capabilities to potentially eradicate cancer, offering improved treatment options with curative potential for patients.

Lilac Solutions, Inc. is a mining technology company based in Oakland, California, specializing in lithium extraction technology. Founded in 2015, the company develops innovative solutions that utilize ion-exchange theory to absorb lithium from brine deposits. This technology includes ion exchange beads and continuous brine processing systems, which enable lithium producers to enhance project development, increase lithium recovery, and optimize operations. Lilac Solutions aims to support industries such as electric vehicles and renewable energy storage by providing methods that reduce both costs and environmental impact associated with lithium production.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Apiture, Inc. is a financial technology company that specializes in developing digital banking solutions for banks and credit unions across the United States. Founded in 2017 and headquartered in Wilmington, North Carolina, with an additional office in Austin, Texas, Apiture offers products such as Apiture Open, which facilitates the opening of checking, savings, CDs, and loan accounts, and Apiture Xpress, an integrated digital banking solution tailored for both consumer and business account holders. The company focuses on empowering financial institutions by providing advanced software that enhances their ability to serve customers efficiently and effectively in today’s digital landscape. Through its API-driven approach, Apiture aims to streamline development processes and enable innovative banking solutions that meet the evolving needs of clients and their customers. Apiture operates as a subsidiary of First Data Corporation and maintains a strategic alliance with DefenseStorm, Inc.

Stash develops a personal finance application to combine banking, investing, and advice into one platform. Its application's services include personal investment accounts, retirement accounts, and custodial accounts for minors. It also provides the option to buy fractional shares of stocks, bonds, and funds with no add-on trading commissions to help users save small sums of money and make micro-investments.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Databricks Inc. is a technology company that provides a unified data analytics cloud platform designed to facilitate data engineering and collaborative data science. The company offers a comprehensive suite of tools, including a just-in-time data platform that simplifies data integration, real-time experimentation, and deployment of production applications for developers and data scientists. Key products include Databricks Delta, which combines the capabilities of data warehouses with low-latency streaming, MLflow for managing the machine learning lifecycle, and Delta Lake for handling batch and streaming data. Databricks serves a diverse range of industries, including advertising, healthcare, manufacturing, and telecommunications, and has established strategic partnerships with various organizations to enhance its offerings. Founded in 2013, Databricks is headquartered in San Francisco, California, with additional offices in London, Amsterdam, and Bengaluru.

Sortera Alloys manufactures low-cost, high-quality metal alloys for domestic manufacturing using its artificial intelligence technology. Sortera Alloys is a company based in Fort Wayne, Indiana, and was established in 2020.

Redwood Materials, Inc. is a Nevada-based company focused on advancing sustainable battery recycling technologies to create a circular supply chain for lithium-ion batteries. Founded by JB Straubel in 2017, Redwood specializes in the recycling and processing of end-of-life batteries and electronics to recover critical materials such as lithium, nickel, cobalt, copper, and various metals. The company currently receives approximately 10 GWh of used batteries annually and aims to scale its production of anode and cathode materials to 100 GWh by 2025, sufficient for manufacturing over one million electric vehicles each year. By providing environmentally sound solutions for recycling and refining, Redwood supports industries including electric vehicles, renewable energy storage, and consumer electronics, thereby contributing to a reduction in the environmental impact of battery production and usage.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for neurological disorders. The company focuses on creating transformational small-molecule therapies aimed at patients with central nervous system conditions. Leveraging foundational research in neuronal receptor biology, Rapport Therapeutics maps and targets specific neuronal receptor complexes, which are complex assemblies of proteins that include principal receptor subunits and receptor-associated proteins. These receptor-associated proteins are essential for regulating receptor expression and functionality, allowing the company to innovate in the treatment of neurological diseases.

Genesis Therapeutics Inc. is a biotechnology company focused on developing small molecule drug candidates aimed at treating patients with severe and debilitating disorders. Established in 2019 and headquartered in South San Francisco, California, the company utilizes a proprietary artificial intelligence platform that integrates deep neural networks, biophysical simulation techniques, and scalable computing infrastructure. This innovative approach enhances the efficiency and accuracy of drug discovery and molecular design, allowing for improved molecular generation and property prediction. By leveraging these advanced technologies, Genesis Therapeutics seeks to transform the drug development process, ultimately aiming to optimize clinical outcomes for patients in need of effective therapies.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Established in 2019, the company specializes in genetic medicine by utilizing a proprietary platform that employs endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in RNA transcripts. This innovative approach aims to restore the production of functional proteins, offering potential treatments for a variety of diseases, including those affecting genetic, cardiometabolic, complement-mediated, and central nervous system areas. ADARx Pharmaceuticals is dedicated to developing life-saving therapeutics that address genetic mutations and provide solutions for conditions that are currently considered incurable.

KoBold Metals is an AI-powered mineral exploration company focused on discovering essential materials for the electric vehicle and renewable energy sectors. The company combines advanced ore-deposit science with big data and scientific computing to enhance mineral exploration efforts. Its data platform aggregates and structures extensive scientific datasets, utilizing machine learning and other sophisticated analytical techniques to predict the composition of subsurface resources. By employing statistical association models and various analytical methods, KoBold Metals helps mineral exploration companies identify new sources of cobalt and other critical materials, thereby contributing to sustainable supply chains for the rapidly growing demand in electric vehicle production.

Retiree Income is a company dedicated to enhancing the financial well-being of retirees and those approaching retirement. The firm focuses on developing retirement income planning software that aims to maximize after-tax income and bequest value over a client's lifetime. By utilizing advanced analytic engines, the software offers personalized income and tax-efficient withdrawal strategies, along with optimal Social Security claiming options. This approach empowers clients to make informed financial decisions, ultimately improving their ability to manage and optimize retirement resources effectively. Retiree Income is committed to providing smarter and more tailored solutions for individuals navigating retirement planning.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative gene therapies utilizing its proprietary Anellovector platform. This platform, based on the human commensal virome, addresses several limitations of existing gene therapies, including restricted access to diverse tissues, challenges in redosing, risks of genomic integration, and issues with tolerability. Founded in 2017 and previously known as VL46, Inc., Ring Therapeutics aims to expand the applications of gene therapy beyond traditional gene replacement. By enabling a broader range of therapeutic modalities and mechanisms, the company seeks to treat a variety of previously inaccessible diseases, including genetic disorders, ophthalmology, oncology, and metabolic conditions.

VerAI Discoveries is an AI-driven mineral asset portfolio company that employs artificial intelligence and machine learning to identify concealed mineral deposits in underexplored terrain. By focusing on prime mining jurisdictions, VerAI enhances the likelihood of discovering significant mineral deposits while reducing economic risks associated with exploration. The company utilizes its advanced platform to analyze complex datasets and trace unique signatures of existing deposits, thereby accelerating the mineral exploration process. VerAI collaborates with industry investors and explorers to develop a diversified portfolio of base and precious metal targets, contributing to the global supply of critical minerals and supporting the transition towards a zero-carbon economy.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing innovative CAR T-cell therapies to improve outcomes for cancer patients. The company aims to address the challenges faced by existing autologous CAR therapies, which are only curative for less than half of cancer patients and hindered by issues such as manufacturing limitations, supply challenges, and reimbursement barriers. Cargo Therapeutics is advancing next-generation cell therapies designed to enhance effectiveness, safety, and supply reliability. One of its key products, CRG-022, is a novel CAR T-cell candidate targeting CD22, an antigen present in a majority of B-cell malignancies, specifically designed to overcome treatment resistance. By pursuing these novel solutions, Cargo Therapeutics seeks to facilitate broader access to curative therapies and significantly improve the treatment experience for cancer patients.

Mirion Technologies is a provider of detection, measurement, analysis, and monitoring solutions focused on the safe use of ionizing radiation across various sectors, including nuclear, defense, and medical applications. The company offers a range of products, services, and software designed to meet the stringent regulatory standards and operational requirements of its clients. Its operations are divided into two main segments: Medical and Technologies. The Medical segment focuses on quality assurance in radiation oncology, ensuring patient safety in diagnostic imaging and radiation therapy. The Technologies segment serves the nuclear energy and defense industries, as well as laboratories and scientific research, enabling safe and effective utilization of radiation in critical applications. Mirion Technologies is committed to leveraging its extensive expertise in radiation to support advancements that benefit humanity.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Jetti Resources, established in 2014 and based in Vancouver, Canada, specializes in developing hydrometallurgical technologies for extracting metals from mineral ores. Its proprietary catalytic technology is primarily used to recover copper from low-grade primary sulfides like chalcopyrite, addressing a significant global resource recovery challenge cost-effectively and responsibly. Additionally, Jetti's technology can be applied to other minerals such as zinc and nickel sulfides, expanding its potential impact on the mining industry.

Celonis is a company that specializes in execution management, focusing on optimizing and analyzing business processes across various industries, including production, human resources, and logistics. Its core product, the Celonis Execution Management System (EMS), utilizes advanced process mining technology to enhance productivity and streamline operations. The EMS provides a comprehensive suite of tools and applications, including Celonis Studio, designed for business executives and users to effectively manage execution across analytics, strategy, planning, and automation. By offering unique software solutions, Celonis enables organizations to improve process transparency and efficiency, ultimately unlocking their full execution capacity.

Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, specializing in targeted protein degradation. Founded in 2015, the company employs a proprietary platform that utilizes the body's natural protein degradation system to selectively degrade disease-causing proteins. Kymera is advancing several therapeutic programs, including its IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. By focusing on previously untreatable conditions and using innovative small molecule modalities, Kymera Therapeutics aims to revolutionize drug discovery and create effective treatments for challenging diseases.

Cleerly is a healthcare company focused on transforming the management of coronary artery disease through innovative digital care pathways aimed at preventing heart attacks. By combining advanced clinical science with state-of-the-art artificial intelligence, Cleerly develops a platform that delivers actionable clinical insights for all stakeholders involved in heart care. This platform employs a non-invasive approach to analyze and characterize plaque buildup in coronary arteries, allowing healthcare providers to better identify at-risk patients and facilitate early treatment. Cleerly's data-driven solutions not only enhance the evaluation of cardiovascular disease but also aim to improve patient heart health while delivering value to the healthcare system.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

YuLife is a technology-driven insurance company founded in 2016 and headquartered in London. The company aims to inspire individuals and transform financial products into a force for good by integrating gamification and behavioral science into its offerings. YuLife provides life and medical insurance plans while promoting wellness by encouraging users to engage in health-related activities such as walking and meditation. Participants can earn rewards, including air miles, vouchers, and gift cards, which are designed to support their financial, emotional, and physical well-being. By focusing on healthy living, YuLife enables businesses to insure their employees while allowing individuals to reap the benefits of a healthier lifestyle.

Flexe, Inc. operates a cloud-based warehousing services marketplace that connects organizations needing additional warehousing and fulfillment services with those that have excess capacity. Founded in 2013 and headquartered in Seattle, the company specializes in omnichannel logistics, providing solutions for eCommerce fulfillment, retail distribution, same-day delivery, and network capacity. By integrating technology with an open logistics network, Flexe enables retailers, wholesalers, manufacturers, and logistics companies to optimize their operations, address inventory overflow, and streamline material handling. This approach allows clients to enhance their distribution networks by accessing affordable warehouse spaces, thereby maximizing revenue potential while maintaining operational efficiency.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, a targeted cancer therapy using gene-engineered allogeneic CAR-NK cells designed to eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A for treating hepatocellular carcinoma.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Convoy, Inc. operates an online marketplace that provides digital freight network services, enabling users to book local and regional trucks on demand for transporting goods of various sizes. Founded in 2015 and based in Seattle, Washington, Convoy utilizes technology and data to enhance efficiency and reduce waste in the trucking industry, which faces significant challenges such as empty truckloads and high carbon emissions. The company facilitates instant quotations, online booking, automated loading suggestions, and online payments, while also offering a mobile application for real-time shipment tracking and status updates. By optimizing its connected network of carriers, Convoy aims to lower costs for shippers, increase earnings for drivers, and contribute to environmental sustainability by minimizing carbon waste.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Cross River Bank, established in 2008 and headquartered in Fort Lee, New Jersey, is a subsidiary of CRB Group, Inc. It offers a range of personal and corporate banking services, including checking, savings, and deposit accounts. The bank specializes in direct lending for commercial real estate projects across the New York, New Jersey, and Connecticut metro areas. Notably, Cross River Bank combines traditional banking with innovative technologies to provide solutions for fintech companies in marketplace lending and payment processing. It focuses on regulatory compliance and consumer protection to deliver secure, API-based banking platforms and products, encompassing lending, payments, risk management, and BaaS offerings, enabling a comprehensive banking experience for its clients.

SandboxAQ is a company that develops artificial intelligence and quantum technology solutions aimed at addressing complex business and scientific challenges. By integrating expertise from multiple disciplines, including physics, computer science, and mathematics, the company creates Large Quantitative Models and AI sensing applications tailored for various industries. Its offerings are designed to provide practical solutions in sectors such as financial services, healthcare, telecommunications, and cybersecurity. Through its innovative software, SandboxAQ enables clients to tackle significant computational challenges and advance their technological capabilities.

PrognomiQ is a technology company specializing in transforming the early detection and treatment of complex diseases like cancer. It generates comprehensive proteomic, genomic, and metabolomic data to provide insights into these conditions, aiming to enhance patient outcomes. The company's innovative approach involves developing advanced test products that improve understanding and management of health issues by integrating diverse health data types.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Rigetti Computing is a full-stack quantum computing company that designs and manufactures quantum-integrated circuits, which are deployed in low-temperature environments. The company develops control systems that perform quantum logic operations and has created software to seamlessly integrate its quantum systems into existing cloud infrastructures. Rigetti is known for its development of the industry's first multi-chip quantum processor, enabling scalable quantum computing systems. Additionally, the company focuses on practical applications of quantum computing, particularly in computational chemistry and machine learning, and has introduced Forest, a comprehensive programming and execution environment for quantum and classical computing. The majority of its revenue is generated from the United States.

Saluda Medical Pty Ltd. is a medical device company specializing in the development of neuromodulation technologies for chronic neurological conditions. Founded in 2010 and based in Artarmon, Australia, with additional offices in the United States and the United Kingdom, Saluda Medical focuses on its innovative Evoke system. This investigational device employs a closed-loop spinal cord stimulation approach that continuously monitors the spinal cord's response to stimulation and adjusts treatment in real-time to optimize patient outcomes. By utilizing a unique dose-control platform, Saluda Medical aims to customize therapy based on individual neural responses, thereby improving the management of chronic pain, particularly in patients suffering from conditions such as neuropathic pain and chronic back pain.

CelLink Corporation, founded in 2012 and headquartered in Belmont, California, specializes in the development of flexible conductive backplanes and circuits designed for power electronics. The company focuses on creating high-conductance, large-area flexible circuits that integrate multiple functionalities, including busing, fusing, and voltage and temperature monitoring. These innovations are intended for use in a variety of applications such as batteries, light-emitting diodes, wire harnessing, and solar cells, facilitating efficient power transmission. By offering these advanced circuits, CelLink aims to provide customers with affordable solutions that enhance the performance and reliability of their power-related devices.

Epirus, Inc. is a technology company based in Hawthorne, California, specializing in the design and development of advanced defense systems that utilize artificial intelligence and directed energy. Founded in 2018, the company focuses on creating solid-state, software-defined high-power microwave solutions aimed at countering unmanned aircraft systems and other asymmetric threats. Its flagship product, ELECTROMAGNETIC PULSE, serves as a counter-infrastructure solution that can simultaneously target multiple threats, effectively neutralizing drones and swarms. By integrating AI and machine learning with advanced electronics, Epirus enhances the detection and tracking of objects of interest, offering innovative capabilities in electronic warfare and power management for both defense and commercial sectors.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Eikon Therapeutics, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative treatments for chronic and life-threatening diseases. Established in 2019, the company employs advanced super-resolution microscopy and live-cell imaging techniques to discover drugs targeting previously intractable proteins. By directly measuring the interactions of chemical compounds with individual proteins within a live cellular environment, Eikon Therapeutics enhances the understanding of biological processes and supports the development of targeted therapies. The integration of biology, engineering, and chemistry in its proprietary platforms allows Eikon Therapeutics to streamline the drug discovery process, advance clinical programs, and expand its pipeline of potential medications.

SalioGen Therapeutics is a biotechnology company focused on developing innovative gene therapies for inherited disorders. Utilizing its proprietary Exact DNA Integration Technology (EDIT) platform, the company employs mammal-derived enzymes known as Saliogase to facilitate genome engineering. This approach allows for non-viral delivery of genes of any size, offering significant advantages in manufacturing and application. SalioGen's technology aims to provide safe, durable, and affordable solutions that could transform treatment options for patients with genetic conditions, while also enhancing the efficiency of cell therapy and biologics manufacturing within the healthcare sector.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections such as COVID-19. Utilizing modern reversible-covalent chemistry, the company is dedicated to discovering and developing novel oral drug candidates. Its lead product, PBI-0451, is an oral antiviral designed to treat and prevent infections caused by SARS-CoV-2, the virus responsible for COVID-19. Pardes Biosciences aims to enhance patient access to effective treatments, catering to both adult and pediatric populations, while striving to provide convenient and accessible options for those affected by life-threatening viral infections. The company is committed to contributing to global health solutions and improving patient outcomes.

Airtable is a cloud-based software company that provides an intuitive online platform for creating and sharing relational databases. The company enables users to build custom applications tailored to their needs, facilitating tasks such as creating flexible checklists, organizing collections or ideas, and managing customer contacts. With a diverse range of templates available, from home improvement projects to inventory management, Airtable caters to various use cases without requiring users to have prior coding experience. The platform is designed to democratize software creation, empowering individuals and business teams alike to develop the tools that best suit their requirements.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Grab Holdings Inc., headquartered in Singapore, operates a mobile technology platform that integrates city transportation and various on-demand services in Southeast Asia. The company, founded in 2012 by Anthony Tan and Tan Hooi Ling, offers services such as ride-hailing (GrabTaxi, GrabCar), carpooling (GrabHitch, GrabShare), shuttle services (GrabShuttle, GrabShuttle Plus), and food delivery through its GrabFood platform. Grab also provides financial services, including payments, consumer loans, and enterprise offerings. It operates in eight countries: Singapore, Indonesia, Philippines, Malaysia, Thailand, Vietnam, and Myanmar. Grab generates revenue by charging commissions to both consumers and service providers, with ride-hailing and food delivery contributing to 89% of its total revenue. The company competes with Foodpanda and Gojek in the region.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Farmers Business Network, Inc. is an independent agricultural technology and commerce platform that serves as a farmer-to-farmer network, empowering its members to make informed decisions to enhance the economic viability of their farms. The company advocates for family farmers and ranchers by providing data-driven agronomic insights, facilitating direct purchases from manufacturers, and enabling competitive market opportunities for selling crops. Farmers can leverage the network to share information and access vital resources such as health and crop insurance. With a membership that spans over 80 million acres across the U.S., Canada, and Australia, Farmers Business Network employs over 800 personnel and operates offices in key locations, including San Carlos, California, Chicago, Illinois, Sioux Falls, South Dakota, and its Canadian and Australian headquarters in High River, Alberta, and Perth, respectively.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Color is a healthcare technology company that offers a comprehensive platform for population health management, facilitating equitable and accessible healthcare delivery. The company specializes in large-scale health initiatives, providing solutions that include population genomics programs and high-throughput testing services, such as those for COVID-19. By centralizing essential healthcare capabilities, Color enables businesses, schools, and state public health departments to implement effective preventive health programs, regardless of the geographical distribution of their populations. Its innovative approach addresses various healthcare logistics challenges, streamlining processes related to testing, screening, treatment, and referrals, while creating diverse market opportunities and revenue streams for clinical teams.

Socure Inc. is a provider of digital identity verification solutions, focusing on real-time identity authentication through its Socure ID+ platform. This predictive analytics platform utilizes artificial intelligence and machine learning to authenticate identities by analyzing a multitude of online and offline data sources, including email, phone numbers, addresses, IP addresses, and social media profiles. Socure's offerings include Aida, an AI-driven bot for validating digital identities, Docv, an omnichannel document verification solution, and Sigma Synthetic Fraud, which tackles synthetic identity fraud. The company addresses the needs of various sectors, including software, consulting, and financial firms, through compliance initiatives such as customer identification programs, know your customer requirements, and anti-money laundering measures. Founded in 2012 and headquartered in New York, Socure has established partnerships with key industry players to enhance its service delivery.

Nextdoor, Inc. is a social networking platform based in San Francisco that facilitates local conversations among residents. Founded in 2007, the company aims to foster connections within neighborhoods by allowing users to share recommendations, news updates, and resources while also promoting local businesses and services. Nextdoor enhances community engagement by offering features like the Help Map, which enables neighbors to offer assistance to those in need, particularly during crises such as the Covid-19 pandemic. With a presence in multiple countries, including the United States, the United Kingdom, and several European nations, Nextdoor seeks to create a sense of belonging and support among neighbors, emphasizing the importance of community in people's lives.

Aurora Innovation develops advanced software and hardware products for self-driving vehicles, aiming to transform the movement of people and goods. Founded in 2016 and headquartered in Palo Alto, California, the company operates additional offices in the Bay Area, Bozeman, Pittsburgh, and Dallas. Its primary offering, the Aurora Driver, is a scalable self-driving system capable of operating various vehicle types, including freight-hauling trucks and ride-hailing passenger vehicles. This technology supports Aurora's driver-as-a-service products, Aurora Horizon and Aurora Connect, catering to trucking and ride-hailing sectors. By integrating rigorous engineering with applied machine learning, Aurora Innovation seeks to create a comprehensive transportation ecosystem that connects automakers, logistics services, and mobility providers.

Nuro, Inc. is a technology company based in Mountain View, California, that specializes in the development of self-driving vehicles specifically designed for local goods transportation. Incorporated in 2016, Nuro aims to transform local commerce through its fleet of fully autonomous, electric vehicles that facilitate the delivery of a wide range of products, including food and pharmaceuticals. By enabling retailers to efficiently and safely deliver goods to customers, Nuro enhances the convenience of local commerce and meets the growing demand for autonomous delivery solutions.

Rad Power Bikes LLC, based in Seattle, Washington, is North America's largest electric bike brand, incorporated in 2015. The company designs and manufactures electric bicycles suitable for both on and off-road use, offering feature-rich and affordable options tailored to individual needs. In addition to its bikes, Rad Power Bikes provides a range of accessories, including bags, fenders, racks, and safety products, as well as replacement parts like batteries and tires. Utilizing a direct-to-consumer sales model, the company has experienced rapid growth and aims to democratize electric biking, making energy-efficient transportation accessible and enjoyable for a wide audience. With a team of over 700 employees, Rad Power Bikes is committed to transforming the landscape of electric mobility.

Oak Hill Advisors, established in 1991, is a New York-based, privately owned investment manager. It operates as a business development company, providing services to private investment funds. The firm specializes in fixed income investments, primarily in North America and Europe, focusing on leveraged bank loans, high yield bonds, distressed securities, and structured products. Additionally, Oak Hill Advisors invests in private equity, targeting small to mid-sized companies in sectors like energy, healthcare, and consumer services. The firm employs a fundamental value-oriented strategy, investing between $5 million to $100 million per portfolio company, and seeks exits through refinancing or asset sales. It manages various funds, including distressed funds, credit hedge funds, and customized accounts, on behalf of global investors such as pension funds and sovereign wealth funds.

Trumid Financial LLC is a financial technology company based in New York that specializes in electronic trading solutions for the credit market. Founded in 2014, Trumid operates the Trumid Market Center, an electronic trading network specifically designed for corporate bonds, and offers Trumid Bond Stream, a tool that provides TRACE pricing data. The company focuses on enhancing the credit trading experience by integrating advanced technology with market expertise, facilitating direct access to liquidity and valuable market intelligence for professionals in the corporate bond sector. Additionally, Trumid Labs leverages data science to manage its network and provide bond price lookup services, enabling participants to make informed trading decisions. Trumid operates as a subsidiary of Trumid Holdings LLC.

Honor is a leading senior care network and technology platform that focuses on enhancing the quality of life for older adults and their families. Founded in 2014 by Cameron Ring, Monica Lo, Sandy Jen, and Seth Sternberg in San Francisco, California, Honor has established itself as a pioneer in the home care industry. The company offers expert in-home care services for seniors, leveraging an integrated system of third-party care providers. By combining scalable workforce management with personalized care, Honor enables older adults to live safely and comfortably in their own homes. In 2021, Honor expanded its reach by acquiring Home Instead, enhancing its capabilities through a global network and a relationship-based care model. This strategic move positions Honor to address the evolving needs of aging adults and professional caregivers worldwide.

Coalition, Inc. is an insurance provider based in San Francisco, California, specializing in cyber risk management. Founded in 2017, the company offers a blend of comprehensive insurance coverage and proactive cybersecurity tools tailored for various industries, including healthcare, retail, technology, and more. Coalition's Active Risk Platform equips businesses with automated security alerts, threat intelligence, and expert guidance to enhance their resilience against cyber threats. By integrating risk assessment, security protection, and response capabilities, Coalition enables organizations to effectively mitigate and prevent potential cyber-attacks and associated losses. The company serves clients in the United States and Canada while providing its security solutions globally, supported by prominent global insurers.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Canva, Inc. is a graphic design software provider based in Surry Hills, Australia, established in 2012. The company operates an online platform that enables users to create a variety of visual content, including presentations and social media graphics, using an intuitive drag-and-drop interface. Canva offers a diverse library of layouts, images, photo filters, icons, and fonts, which allows users to personalize their designs without needing advanced software skills. Additionally, Canva provides a plug-in called Canva Button for third-party websites, facilitating graphic creation for their users. The platform serves a wide range of customers, including photographers, illustrators, and designers, with the goal of making design more accessible to everyone.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

Checkr, Inc. is a technology-driven company focused on the background check industry, offering a comprehensive range of screening services, including criminal record checks, driving checks, and identity verification. Founded in 2014 and headquartered in San Francisco, California, Checkr utilizes advanced technology and data sources to deliver faster and more efficient background checks compared to traditional providers. The company emphasizes fairness and transparency in hiring, enabling businesses across various sectors, including financial services, healthcare, and staffing, to enhance their hiring processes. Checkr also provides compliance services and security solutions, ensuring a secure and streamlined experience for both employers and candidates. With its innovative platform, Checkr aims to improve the overall applicant experience while supporting companies in navigating the complexities of today's workforce dynamics.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.